Ovarian cancer future or investigational therapies

	Ovarian cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classifications
Pathophysiology
Causes of Ovarian cancer
Differentiating Ovarian cancer from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
History & Symptoms
Physical Examination
Staging
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ovarian cancer future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ovarian cancer future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ovarian cancer future or investigational therapies
CDC on Ovarian cancer future or investigational therapies
Ovarian cancer future or investigational therapies in the news
Blogs on Ovarian cancer future or investigational therapies
Directions to Hospitals Treating Ovarian cancer
Risk calculators and risk factors for Ovarian cancer future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

Epithelial ovarian cancer patients can have better prognosis and outcome with some under trial Medications that believed to be promising in the future
Examples of the mechanism of action of these promising drugs are:
- Targeting the angiogenesis
- Targeting (inhibit) DNA repair
- Targeting cell cycle
- Targeting signaling pathways
- Immunotherapeutic medications